Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias - PubMed
2 days ago
- #CAR T cell therapy
- #leukemia
- #ferritin
- CAR T cell therapy faces challenges due to antigen modulation causing resistance in leukemia treatment.
- Both leukemia cells and CAR T cells express CD71, a ferritin receptor, which was utilized in the study.
- A ferritin aggregation cell engager (FACE) was designed to anchor to CAR T cells, guiding them to leukemia cells and enhancing antigen recognition.
- FACE-CAR T cells showed improved therapeutic efficacy in vitro and in vivo, with good biosafety and the ability to lower the antigen threshold for overcoming resistance.
- The approach also allows for loading chemodrugs into ferritin for combination therapy, offering a versatile method to enhance CAR T cell therapy for refractory leukemias.